Back to mobile site

TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'

June 10, 2026 1:37 PM EDT Send to a Friend
TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments "SNY stopping riliprubart's MOBILIZE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login